Ex vivo assays demonstrate potency and selectivity of the COX-2 inhibitor DFP after single dose administration.
Dallob
A
A
Merck & Co., Inc., Rahway, NJ 07065, USA. aimee_dallob@merck.com
De Lepeleire
I
I
Van Hecken
A
A
Porras
A
A
Depré
M
M
Mukhopadhyay
S
S
Flynn
M
M
Wildonger
L
L
Gottesdiener
K
K
Tanaka
W
W
De Schepper
P
P
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001555:Benzene Derivatives / Q000494:pharmacology*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D007527:Isoenzymes / Q000187:drug effects*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects*
C404485:3-2(-propyloxy)-(4-methylsulfonylphenyl)-(5,5-dimethyl)furanone; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001555:Benzene Derivatives; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D005663:Furans; D007527:Isoenzymes; D008070:Lipopolysaccharides; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone